Kornimate/medical-research-clean huggingface dataset:
a continuation study using sunitinib malate for patients leaving treatment on a previous sunitinib study.

Conditions: Metastatic Breast Cancer; Advanced Breast Cancer; Metastatic Castration Resistant Prostate Cancer; Metastatic Renal Cell Cancer; Non-Small Cell Lung Cancer; Thyroid Cancer; Advanced/Metastatic Non-Small Cell Lung Cancer; Advanced Gastric Cancer; Gastrointestinal Stromal Tumor; Hepatocellular Carcinoma; Pancreatic Islet Cell Carcinoma; Pancreatic Neuroendocrine Tumor

Summary: this is a study using sunitinib for patients ending treatment on a previous sunitinib malate protocol to continue to receive sunitinib. the patient must have been enrolled in one of the following studies: a6181030, a6181064, a6181078, a6181087, a6181094, a6181107, a6181108, a6181110, a6181111, a6181112, a6181113, a6181120, a6181126 and a6181170. other pfizer sponsored sunitinib studies may be included in the future.


Eligibility criteria:
inclusion criteria: * must have ended treatment from one of the following sunitinib studies: a6181030, a6181064, a6181078, a6181087, a6181094, a6181107, a6181108, a6181110, a6181111, a6181112, a6181113, a6181120, a6181126 and a6181170. other pfizer sponsored sunitinib studies may be included in the future. exclusion criteria: * see inclusion criteria

Keywords: potentially other tumor types in the future
dentin bridge formation after indirect pulp capping with bioactive glass incorporated in resin composite and its adhesive in comparison with light cured calcium hydroxide

Conditions: Pulp Disease, Dental; Dental Caries

Summary: the aim of this study is to evaluate the effect of application of bioactive glass in different protocols on the formation of dentin bridge after indirect pulp capping using resin composite with its adhesive both are containing bioactive glass.


Eligibility criteria:
inclusion criteria: * active carious lesion in deep dentin of molars. * absence of cavitated lesions at the buccal or lingual surfaces as determined by clinical and radiographic examination. * absence of clinical diagnosis of pulp exposure, fistula, swelling of periodontal tissues, and abnormal tooth mobility; * absence of clinical symptoms of irreversible pulpitis, such as spontaneous pain or sensitivity to pressure; * the extension of the carious lesion should be such that complete caries removal would risk pulp exposure, as determined by clinical and radiographic assessment; * absence of radiolucencies at the interradicular or periapical regions, or thickening of the periodontal spaces, that would indicate the presence of irreversible pulp pathologies or necrosis; * absence of internal or external root resorption. * co-operative patients approving the trial. exclusion criteria: * patients with systemic medical conditions * pregnant females * teeth with spontaneous pain or sensitivity to percussion. * teeth with periodontal lesions, internal or external root resorption, mobility of tooth, sinus opening, or abscessed tooth. * radiographic examination revealed, interrupted or broken lamina dura, widened periodontal ligament space, periapical radiolucency.
knowledge attitudes behaviours and practices regarding hiv of men who have sex with men in the french antilles and french guiana

Conditions: Hiv

Summary: determine the knowledge attitudes behaviours and practices regarding hiv of men who have sex with men in the french antilles and french guiana


Eligibility criteria:
inclusion criteria: * men who have sex with men aged over 18 exclusion criteria: * refusal to participate
cd19 car-t therapy for patients with b-cell non-hodgkin's lymphoma

Conditions: Non-hodgkin Lymphoma,B Cell

Summary: a study of cd19 car-t therapy for patients with b-cell non-hodgkin's lymphoma.

this is a single arm, open-label, single-center study. this study is indicated for patients with cd19+ non-hodgkin's lymphoma. the selections of dose levels and the number of subjects are based on clinical trials of similar foreign products. 36 patients will be enrolled. primary objective is to explore the safety, main consideration is dose-related safety.

Eligibility criteria:
inclusion criteria: 1. age no less than 18, no gender limit; 2. histologically confirmed diagnosis of hgbcl（hgbcl-nos、hgbcl involving combined rearrangements of myc, bcl-2 and bcl-6）dlbcl、not otherwise specified and ipi≥3; 3. newly diagnosed b-nhl, unwilling to receive rchop first- or second-line chemotherapy, but willing to receive targeted drugs (such as a regimen consisting of cd20 monoclonal antibody，lenalidomide and brutons tyrosine kinase inhibitor for two courses) as preconditioning regimens for car-t cell therapy; 4. patients with pr or sd efficacy evaluated by pet-ct after two courses of tumor reduction therapy; 5. total bilirubin ≤ 51 umol/l, alt and ast ≤ 3 times of upper limit of normal, creatinine ≤ 176.8 umol/l; 6. echocardiogram shows left ventricular ejection fraction (lvef) ≥50%; 7. no active infection in the lungs, blood oxygen saturation in indoor air is ≥ 92%; 8. estimated survival time ≥ 3 months; 9. ecog performance status 0 to 2; 10. patients or their legal guardians volunteer to participate in the study and sign the informed consent. exclusion criteria: 1. history of craniocerebral trauma, conscious disturbance, epilepsy, cerebrovascular ischemia, and cerebrovascular, hemorrhagic diseases; 2. electrocardiogram shows prolonged qt interval, severe heart diseases such as severe arrhythmia in the past; 3. patients with severe active infections (excluding simple urinary tract infection and bacterial pharyngitis); 4. active infection of hepatitis b virus or hepatitis c virus; 5. previously treated with any car-t cell product or other genetically modified t cell therapies; 6. insufficient amplification capacity in response to cd3 / cd28 co-stimulus signal (\<5 times) ; 7. creatinine\>2.5mg/dl, or alt / ast \> 3 times of normal amounts, or bilirubin\>2.0 mg/dl; 8. other uncontrolled diseases that were not suitable for this trial; 9. patients with hiv infection; 10. any situations that the investigator believes may increase the risk of patients or interfere with the results of study.

Keywords: non hodgkin lymphoma car t-cell therapy cd19
tesetaxel as second-line therapy for patients with advanced gastric cancer

Conditions: Adenocarcinoma of the Stomach; Adenocarcinoma of Esophagogastric Junction

Summary: tesetaxel is an orally administered chemotherapy agent of the taxane class. this study is being undertaken to evaluate the efficacy and safety of tesetaxel administered as second-line therapy to patients with advanced gastric cancer.


Eligibility criteria:
primary inclusion criteria: * confirmed diagnosis of adenocarcinoma of the stomach or esophagogastric junction * measurable disease (revised recist; version 1.1) based on computed tomography * eastern cooperative oncology group performance status 0 or 1 * treatment with only 1 prior regimen (as first-line therapy) and that regimen included a fluoropyrimidine and/or a platinum analogue * documented disease progression within 4 months of the last dose of the 1 prior regimen * adequate bone marrow, hepatic, and renal function, as defined in the protocol * at least 4 weeks and recovery from effects of prior surgery or other therapy, including immunotherapy, radiation therapy, or cytokine, biologic or vaccine therapy, with an approved or investigational agent * ability to swallow an oral solid-dosage form of medication primary exclusion criteria: * nonmeasurable disease only (revised recist; version 1.1) * history or presence of brain metastasis or leptomeningeal disease * operable gastric cancer or operable cancer of the esophagogastric junction * uncontrolled diarrhea, defined as more than 3 loose bowel movements above the patient's usual number of bowel movements on at least 2 days within the 14 days prior to enrollment * uncontrolled nausea or vomiting within the 14 days prior to enrollment despite the administration of standard antiemetic therapy * known malabsorptive disorder * significant medical disease other than cancer, as defined in the protocol * presence of neuropathy \> grade 1 (national cancer institute common toxicity criteria \[nci ctc\]; version 4.0) * prior treatment with a taxane or other tubulin-targeted agent (eg, indibulin) other than a vinca alkaloid * need to continue any regularly-taken medication that is a potent inhibitor or inducer of the cyp3a pathway or p-glycoprotein activity
metabolomics non selection study - vitrolife media

Conditions: Infertility

Summary: in this study, study investigators will collect embryo culture media on day 5 of vitro fertilization (ivf) culture, prior to vitrification and embryo transfer for testing via metabolomic screening. metabolomics is a new, non-invasive method of embryo selection which involves testing discarded embryo culture media for analytes secreted by the developing embryo. these analytes can be used to determine the implantation potential, and ploidy, of the embryo.

patients will undergo a routine ivf cycle. this will include ovarian stimulation, egg retrieval and fertilization of oocytes through intracytoplasmic sperm injection (icsi). all fertilized oocytes will be cultured up to blastocyst for five to six days. spent media will be collected on day 5-6 for all embryos reaching blastocyst on day 5, and on day 6 for those reaching blastocyst on day 6. the spent culture media will be sent to a lab for metabolomic analysis. for the embryo transfer, the best morphology blastocyst will be selected for transfer by the new hope embryologist. approximately 8-11 days after the embryo transfer, the patient will return to the clinic for a serum pregnancy test. should the test be negative, they will be closed out of the study. should the test be positive, they will continue to be monitored. the patient will return to the clinic at approximately 8 weeks after embryo transfer for a serum pregnancy test, and an ultrasound to detect fetal heartbeat. the outcome will be documented and the patient closed out of the study at this time. the embryo transfer outcome will be compared to the metabolomics result to determine the npv and ppv of metabolomics vs implantation.

Eligibility criteria:
inclusion criteria: * women of any age, 25% of patients \ 40 years. * signed subject consent form. no inferior limit on number of eggs exclusion criteria: at the time of initial visit: * require or request pgt of any kind * low ovarian reserve defined as follicle stimulating hormone (fsh) \>10 iu/l on day 2-4 of a prior menstrual cycle and anti-mullerian hormone (amh) \<15 pmol/l (or \<2 ng/ml) within prior 12 months of cycle start at the time of embryo selection: -patients without at least one embryo to transfer.

Keywords: ivf genetic screening preimplantation genetic testing
cognitive impairment and outcome of acute ischemic stroke.

Conditions: Ischemic Stroke; Cognitive Impairment; Outcome, Fatal

Summary: the aim of this study is to assess the use of aspects and stroke biomarkers to predict the outcome and cognitive impairment in acute ischemic stroke.

150 patients (79 males, and 71 females with a mean age of 64.05±11.55 years) were included in this study presented by acute middle cerebral artery territory ischemic stroke. vascular risk factors were determined from the history taking. assessment of gcs and nihss at the initial presentation was done to assess the stroke severity. cognitive functions were evaluated in all study participants by the montreal cognitive assessment (moca) arabic version. an initial and follow up non-contrast ct brain was done after 7 days which were assessed by aspects. functional outcomes in stroke cases were assessed after three months by glasgow coma scale, national institutes of health stroke scale and modified rankin scale. biomarkers of cognitive impairment like esr, crp, s100b, mmp9 and glutamate were evaluated.

Eligibility criteria:
inclusion criteria: * first attack of acute mca territory infarction within 2 days from the onset. exclusion criteria: * previous stroke, * presence of anterior cerebral artery infarction, * posterior cerebral artery infarction, and * venous infarction.

Keywords: stroke; aspeacts, modified rankin scale, national institutes of health stroke scale. higher cortical functions, biomarkers of cognitive impairment.
evaluation of pain in the course of in vitro fertilization

Conditions: Infertility

Summary: 25 to 50% of endometriotic patients are infertile and use medically assisted procreation. in general, the assessment of pain in medically assisted procreation is very little studied. pain assessment studies in endometriotic patients remain limited to a quantitative assessment of pain symptomatology, without contextualization of painful manifestations. the primary objective of our study is the qualitative and contextualized assessment of pain during in vitro fertilization (ivf) protocol in endometriotic and non-endometriotic patients. the secondary objectives of our study are the quantitative study of pain, the measurement of the impact of personal efficiency on painful symptomatology, evaluation of depression, the results of ivf (implantation, pregnancy and live birth rates), and compare pain between endometriotic or non-endometriotic patients and between primary infertility and secondary infertility. according to the results obtained in this study, therapeutic strategies for the management of pain could be proposed, with the aim of improving the quality of life and the results of ivf in these patients.


Eligibility criteria:
inclusion criteria: * all patients who start an ivf cycle in the medically assisted procreation department of the jeanne de flandres hospital (chru lille) exclusion criteria: * refusal to participate in the study * minor patient * patient over 43 years old * bmi patient \> 35 * pregnant woman * unable to provide clear information to the patient * patient under guardianship or lack of health cover * patient in ivf with donation of oocyte * ivf patients for oocyte preservation * patient who had already participated in the study

Keywords: infertility in vitro fertilization endometriosis pain evaluation
nanoknife low energy direct current (ledc) system in subjects with locally advanced unresectable pancreatic cancer

Conditions: Pancreatic Adenocarcinoma

Summary: the purpose of this study is to evaluate the safety and feasibility of the nanoknife low energy direct current (ledc) system when used to treat unresectable pancreatic adenocarcinoma. safety will be reviewed by means of analysis of adverse events, including serious adverse events, laboratory data, physician exam findings, and vital signs.


Eligibility criteria:
inclusion criteria: 1. male or female 2. \>/= 18 years of age 3. meets criteria for locally advanced unresectable pancreatic adenocarcinoma, as radiographically proven pancreatic cancer as determined by a surgical oncologist via pancreatic ct or who were initially thought to be resectable; however at the time of surgery were upstaged to unresectability, via direct visualization 4. tumor size must be \< 4 cm and must be measurable 5. must have an inr \<1.5 6. must be unresponsive to chemotherapy as demonstrated with either ct or mr imaging and not have taken any chemotherapy agents within 14 days of treatment with the nanoknife ledc system 7. are willing and able to comply with the protocol requirements 8. are able to comprehend and willing to sign an informed consent form (icf) exclusion criteria: 1. a baseline creatinine reported as \> 2.0 mg/dl 2. have any reported baseline lab values with a grade 3 or 4 toxicity as defined by the ctcae version 3.0 3. inability to stop antiplatelet and coumadin therapy for 7 days prior to and 7 days post treatment with the nanoknife system 4. known history of contrast allergy that cannot be medically managed 5. known hypersensitivity to the metal in the electrodes (stainless steel 304l) that cannot be medically managed 6. unable to be treated with a muscle blockade agent (e.g. pancuronium bromide, atracurium, cisatracurium, etc) 7. women who are pregnant or currently breast feeding 8. women of childbearing potential who are not utilizing an acceptable method of contraception 9. have taken an investigational agent within 30 days of visit 1 10. have implanted cardiac pacemakers or defibrillators 11. have implanted electronic devices or implants with metal parts in the immediate vicinity of a lesion 12. have a history of epilepsy or cardiac arrhythmia (atrial or ventricular fibrillation) 13. have a recent history of myocardial infarction (within the past 2 months) 14. have q-t intervals greater than 550 ms unless treated with an accysync model 72 synchronization system controlling the nanoknife system's output pulses.

Keywords: locoregional cancer therapy pancreatic cancer unresectable pancreatic cancer pancreatic adenocarcinoma locally advanced, unresectable pancreatic cancer pancreatic cancer tumor ablation nanoknife tumor ablation for pancreatic cancer nanoknife ledc system tumor ablation non thermal ablation irreversible electroporation for pancreatic cancer treatment ire for unresectable pancreatic cancer
effect of espb on postoperative pain in patients with breast cancer implant reconstruction

Conditions: Mammary Cancer; Erector Spinae Plane Block; Postoperative Pain

Summary: nowadays, the incidence of breast cancer is the first number of malignant tumors, and the primary treatment method is surgery.with the development of medical technology and concept, radical mastectomy combined breast reconstruction are becoming more and more popular.but the reconstruction caused greater trauma and more severe postoperative pain.espb is a new nerve block method which thought to reduce pain after thoracic and breast surgery.however, there are few studies on radical mastectomy combined breast reconstruction. so, this randomized controlled study is conducted to explore its impact on postoperative pain and thus provide more data guidance for clinical.

patients: 100 breast cancer patients who are planned radical mastectomy combined breast reconstruction intervention: general anesthesia + erector spinae plane block control ： general anesthesia outcome: nrs(numerical rating scale) of postoperative pain at the sixth hour study:rct

Eligibility criteria:
inclusion criteria: * patients scheduled for an radical mastectomy and implant reconstruction surgery * patients with american society of anesthesiologists (asa) physical status i-ii, * aged 18-70 years exclusion criteria: * coagulation disorders, * known allergy to study drugs, * obesity (body mass index \> 35 kg/m2), * infection at the injection site, * chronic opioid consumption, and an inability to use patient-controlled analgesia (pca) device, * patient refuse

Keywords: mammary cancer implant reconstruction erector spinae plane block postoperative pain
the optimal antibiotic treatment duration for community-acquired pneumonia in adults diagnosed in general practice in denmark (cap-d)

Conditions: Community-acquired Pneumonia

Summary: the aim of this randomised controlled trial is to identify the optimal treatment duration with phenoxymethylpenicillin for community-acquired pneumonia diagnosed in general practice. eligible participants are adults (≥18 years) presenting in general practice with symptoms of an acute lrti (i.e., acute illness (≤ 21 days) usually with cough and minimum one other symptom such as dyspnea, sputum production, wheezing, chest discomfort or fever) in whom the gp finds it relevant to treat with antibiotics. consenting patients who meet all the eligibility criteria will be randomised (1:1:1:1:1) to either three, four, five, six or seven days of treatment with phenoxymethylpenicillin 1.2 mie four times daily.


Eligibility criteria:
inclusion criteria: eligible participants are adults (≥18 years) presenting in general practice with symptoms of an acute lrti (i.e., acute illness (≤ 21 days) usually with cough and minimum one other symptom such as dyspnoea, sputum production, wheezing, chest discomfort or fever) in whom the gp finds it relevant to treat with antibiotics. exclusion criteria: 1. need for immediate hospitalisation at the time of diagnosis. 2. known allergy to beta-lactam antibiotics. 3. any coinfection necessitating antibiotic treatment. 4. use of systemic antibiotics or antivirals within the last month. 5. pre-existing lung disease (e.g., chronic obstructive pulmonary disease, bronchiectasis, asthma, lung cancer). 6. known immunosuppression (i.e., long term treatment with corticosteroid, chemotherapy, or immune disorder). 7. pregnant or lactating. 8. patients not capable of consenting and/or patients deemed non-suitable for participation by the healthcare professional.

Keywords: community-acquired pneumonia treatment duration phenoxymethylpenicillin general practice
buprenorphine formulation comparison: sublingual tablet vs. solution - 1

Conditions: Opioid-Related Disorders

Summary: the purpose of this study is to compare subject response to liquid vs. tablet formulations, to assess bioequivalency of liquid vs. tablet, to compare subject preference, and to evaluate if dose response curve for tablet is equal to liquid form."

1) compare subjects response to liquid vs tablet formulation 2) assess bioequivalency of liquid vs tablet 3)compare subject preference 4) evaluate if dose response curve for tablet = to liquid form

Eligibility criteria:
inclusion criteria: m/f ages 18-65. meet dms-iv criteria for opiate dependence. agree to conditions of the study and sign informed consent. exclusion criteria: pregnant or nursing women. acute medical condition that would interfere with study participation or put safety of subjects in jeopardy. current daily use of anti-convulsants, antabuse or neuroleptics. dsm-iv diagnosis of etoh or sedative/hypnotics dependence.

Keywords: opioid dependence
validation of a 13c glucose breath test compared with the euglycaemic clamp test

Conditions: Insulin Resistance; Type 1 Diabetes

Summary: insulin resistance can be assessed by the euglycaemic clamp technique. to date, this is the golden standard, but it is not suited for clinical practice. a 13c glucose breath test will be tested as a valid alternative. the curve of the exhaled 13c co2 as a function of glucose metabolism can be correlated to the curve of the glucose disposal rate obtained via the clamp technique.

the hyperinsulinemic-euglycemic clamp technique is the golden standard to assess insulin resistance in type 1 diabetes subjects. the plasma insulin concentration is acutely raised and maintained at 100 μu/ml by a continuous infusion of insulin. meanwhile, the plasma glucose concentration is held constant at basal levels by a variable glucose infusion. when the steady-state is achieved, the glucose infusion rate equals glucose uptake by all the tissues in the body and is therefore a measure of tissue insulin sensitivity. these data will be compared with the results of a 13c glucose breath test. breath tests using 13c substrates are based on the principle that 13c co2 in the exhaled breath can be measured as a metabolic tracer. breath testing has a major advantage over the clamp test in that it can be performed non-invasively and repeatedly without necessary supervision by medical staff.

Eligibility criteria:
inclusion criteria: * adult type 1 diabetes patients * 25/50 subjects with confirmed nafld (using ultrasound criteria) exclusion criteria: * pregnancy * gastric bypass surgery * cirrhosis * secondary cause of liver steatosis present * any cause which makes a 4-hour clamp impossible

Keywords: insulin resistance type 1 diabetes euglycaemic clamp breath test